Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.

Neuro-oncology - 29 Sept 2020

Bailey Cavan P, Figueroa Mary, Gangadharan Achintyan, Yang Yanwen, Romero Megan M, Kennis Bridget A, Yadavilli Sridevi, Henry Verlene, Collier Tiara, Monje Michelle, Lee Dean A, Wang Linghua, Nazarian Javad, Gopalakrishnan Vidya, Zaky Wafik, Becher Oren J, Chandra Joya

Abstract excerpt

BACKGROUND: Diffuse midline gliomas (DMG), including brainstem diffuse intrinsic pontine glioma (DIPG), are incurable pediatric high-grade gliomas (pHGG). Mutations in the H3 histone tail (H3.1/3.3-K27M) are a feature of DIPG, rendering them therapeutically sensitive to small-molecule inhibition of chromatin modifiers. Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) is clinically relevant but...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Stem Neoplasms
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Histones

Share to Lysine

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 32166329
DOI: 10.1093/neuonc/noaa058
PMCID: PMC7523459

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.PMID 32166329Read ↗

Pharmacologic inhibition of lysine specific demethylase-1 (LSD1) as a therapeutic and immune-sensitization strategy in diffuse intrinsic pontine glioma (DIPG)Semantic proximity Read ↗

Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M GliomasSemantic proximity Read ↗

Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine gliomaSemantic proximity Read ↗

Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.Semantic proximity Read ↗

H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity Read ↗

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.Semantic proximity Read ↗

Diffuse Intrinsic Pontine Glioma : Clinical Features, Molecular Genetics, and Novel Targeted TherapeuticsSemantic proximity Read ↗

Comprehensive molecular characterization of pediatric treatment-induced high-grade glioma: A distinct entity despite disparate etiologies with defining molecular characteristics and potential therapeutic targetsSemantic proximity Read ↗

Diffuse intrinsic pontine glioma: current insights and future directionsSemantic proximity Read ↗

Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201Semantic proximity Read ↗

Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized therapeuticsSemantic proximity Read ↗

Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.